600673 东阳光
已收盘 12-20 15:00:00
资讯
新帖
简况
东阳光创近1年新高 3券商买入
智选洞察 · 12-19 14:15
东阳光创近1年新高 3券商买入
政策给力 实施股票回购增持贷款公司已超200家
美港电讯 · 12-18 05:29
政策给力 实施股票回购增持贷款公司已超200家
东阳光12月17日获主力加仓1117万元 环比增加398.66%
市场透视 · 12-17
东阳光12月17日获主力加仓1117万元 环比增加398.66%
东阳光药基于AI驱动的首个小分子创新药HEC169584胶囊获批临床
智通财经网 · 12-16
东阳光药基于AI驱动的首个小分子创新药HEC169584胶囊获批临床
IPO观察：东阳光药赴港IPO奥司他韦销量第一，古茗再次递表港交所
洞察IPO · 12-16
IPO观察：东阳光药赴港IPO奥司他韦销量第一，古茗再次递表港交所
东阳光12月16日主力资金流入224万元 连续5日加仓
市场透视 · 12-16
东阳光12月16日主力资金流入224万元 连续5日加仓
东阳光药上市在即：深筑差异化创新壁垒，研产销一体化竞争优势催化价值成长
智通财经 · 12-16
东阳光药上市在即：深筑差异化创新壁垒，研产销一体化竞争优势催化价值成长
东阳光药冲刺港交所上市：上半年营收、利润双降，张寓帅子承父业
贝多财经 · 12-13
东阳光药冲刺港交所上市：上半年营收、利润双降，张寓帅子承父业
东阳光药整合上市全面加速，实现1+1＞2？
乐居财经 · 12-13
东阳光药整合上市全面加速，实现1+1＞2？
东阳光药业冲刺港股：上半年营收25.8亿 同比降20.7%
腾讯自选股 · 12-12
东阳光药业冲刺港股：上半年营收25.8亿 同比降20.7%
医健IPO解码｜手握流感“神药”，东阳光药递交港交所上市申请
21世纪经济报道 · 12-12
医健IPO解码｜手握流感“神药”，东阳光药递交港交所上市申请
港股异动 | 东阳光长江药业(01558)盘中涨近9% 控股股东东阳光药业递交招股书 拟以介绍方式在港上市
智通财经 · 12-12
港股异动 | 东阳光长江药业(01558)盘中涨近9% 控股股东东阳光药业递交招股书 拟以介绍方式在港上市
东阳光12月12日主力资金流入1452万元 连续3日加仓
市场透视 · 12-12
东阳光12月12日主力资金流入1452万元 连续3日加仓
东阳光药向香港交易所提交招股书 以介绍方式上市
观点地产网 · 12-12
东阳光药向香港交易所提交招股书 以介绍方式上市
东阳光药递交招股书 拟以介绍方式在港上市
美港电讯 · 12-12
东阳光药递交招股书 拟以介绍方式在港上市
东阳光药业拟重组东阳光长江药业并以介绍形式香港上市，递交上市申请
市场资讯 · 12-12
东阳光药业拟重组东阳光长江药业并以介绍形式香港上市，递交上市申请
【新股IPO】广东东阳光药业向港交所主板提交上市申请
金吾财讯 · 12-12
【新股IPO】广东东阳光药业向港交所主板提交上市申请
即将登陆港股市场，挖掘东阳光药研产销一体化创新布局背后的投资机会
智通财经 · 12-11
即将登陆港股市场，挖掘东阳光药研产销一体化创新布局背后的投资机会
东阳光12月06日主力资金流入2698万元 连续3日加仓
市场透视 · 12-06
东阳光12月06日主力资金流入2698万元 连续3日加仓
东阳光（600673）2名股东合计质押7300万股，占总股本2.42%
证券之星 · 12-06
东阳光（600673）2名股东合计质押7300万股，占总股本2.42%
加载更多
公司概况
公司名称：
广东东阳光科技控股股份有限公司
所属行业：
综合
上市日期：
1993-09-17
主营业务：
广东东阳光科技控股股份有限公司的主营业务为电子元器件、高端铝箔、化工新材料、能源材料四大板块业务。主要产品有铝电解电容器用电极箔(包含腐蚀箔和化成箔)、积层箔、铝电解电容器、软磁材料、电子光箔、亲水箔、钎焊箔、电池铝箔、氯碱化工产品、新型环保制冷剂、磷酸铁锂、三元材料等。公司被评为国家技术中心(“广东省工程技术研发中心”)。
发行价格：
3.80
{"stockData":{"symbol":"600673","market":"SH","secType":"STK","nameCN":"东阳光","latestPrice":9.25,"timestamp":1734678000000,"preClose":9.15,"halted":0,"volume":29879802,"delay":0,"floatShares":3002000000,"shares":3014000000,"eps":0.0796,"marketStatus":"已收盘","marketStatusCode":5,"change":0.1,"latestTime":"12-20 15:00:00","open":9.2,"high":9.35,"low":9.14,"amount":276000000,"amplitude":0.023,"askPrice":9.26,"askSize":200,"bidPrice":9.25,"bidSize":34,"shortable":0,"etf":0,"ttmEps":0.0796,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":9.15,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":10.07,"lowLimit":8.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3013874259,"pbRate":3.07,"roa":"--","roe":"3.13%","epsLYR":-0.1,"committee":-0.598718,"marketValue":27878000000,"floatMarketCap":27764000000,"peRate":116.206032,"changeRate":0.0109,"turnoverRate":0.01,"status":0},"requestUrl":"/m/hq/s/600673","defaultTab":"news","newsList":[{"id":"2492812957","title":"东阳光创近1年新高 3券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2492812957","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492812957?lang=zh_cn&edition=full","pubTime":"2024-12-19 14:15","pubTimestamp":1734588939,"startTime":"0","endTime":"0","summary":"12月19日，东阳光股价大幅上涨，截至14点15分，东阳光上涨5.33%，报9.28元/股，创近1年新高，成交2.28亿元，换手率0.84%。此外，数据统计显示，近半年内3家券商给予买入建议。资金动向截止发稿，东阳光获得主力净流入1966万元，其中超大单流入2434万元，大单流出467万元。最新财报显示，今年三季报，东阳光实现营业收入88.79亿元，同比增长9.51%，净利润为3.12亿元，同比增长241.04%，基本每股收益为0.11元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121914154495ea6bfb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121914154495ea6bfb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0188","BK0028","BK0012","BK0265","600673","BK0003"],"gpt_icon":0},{"id":"2492913572","title":"政策给力 实施股票回购增持贷款公司已超200家","url":"https://stock-news.laohu8.com/highlight/detail?id=2492913572","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492913572?lang=zh_cn&edition=full","pubTime":"2024-12-18 05:29","pubTimestamp":1734470986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1541","BK1505","399300","BK0274","BK0176","601598","BK0233","BK0139","BK0003","BK0012","LU1051768304.USD","LU1166156734.SGD","BK0028","LU0651946864.USD","159982","BK1535","BK0000","LU1781817850.SGD","BK0237","00598","601609","BK1502","BK1151","BK0183","BK0010","BK0196","BK0265","600673","BK0070","BK0015","LU1515016050.SGD","BK0025","BK0188","LU0702159699.USD","BK0006","002203","LU0702159343.USD","600028","LU1580142542.USD"],"gpt_icon":0},{"id":"2492958437","title":"东阳光12月17日获主力加仓1117万元 环比增加398.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492958437","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492958437?lang=zh_cn&edition=full","pubTime":"2024-12-17 15:18","pubTimestamp":1734419915,"startTime":"0","endTime":"0","summary":"12月17日, 东阳光股价涨2.61%，报收9.05元，成交金额2.31亿元，换手率0.86%，振幅4.99%，量比1.06。东阳光今日主力资金净流入1117万元，连续6日净流入，上一交易日主力净流入224万元，今日环比增加398.66%。近一年数据显示，该股主力连续6日净流入后，次日上涨概率为40.00%，平均涨幅为1.78%。该股近5个交易日上涨3.55%，主力资金累计净流入7514万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.30亿元，其中净流入天数为17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217152453a1f52129&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217152453a1f52129&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600673","BK0188","BK0265","BK0003","BK0070","BK0028","BK0012"],"gpt_icon":0},{"id":"2491665550","title":"东阳光药基于AI驱动的首个小分子创新药HEC169584胶囊获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2491665550","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491665550?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:34","pubTimestamp":1734345247,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2024年12月16日，广东东阳光药业股份有限公司、杭州东阳光药业有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准1类新药HEC169584胶囊开展用于非酒精性脂肪性肝炎的临床试验。通过上述AI技术手段，公司最终确定具有良好体内外药效、成药性和安全性的候选药物HEC169584。目前国内尚无同类药物上市，HEC169584有望快速推进临床，为患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0265","600673","BK0028","BK0003","BK0188","BK0012","BK0070"],"gpt_icon":0},{"id":"2491665561","title":"IPO观察：东阳光药赴港IPO奥司他韦销量第一，古茗再次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2491665561","media":"洞察IPO","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491665561?lang=zh_cn&edition=full","pubTime":"2024-12-16 18:07","pubTimestamp":1734343620,"startTime":"0","endTime":"0","summary":"终止上市审核12月9日-12月15日，上交所、深交所均无公司终止上市审核。递交上市申请12月9日-12月15日，港交所有6家公司递交上市申请。东阳光药于12月11日披露招股书拟登陆港交所主板12月11日，广东东阳光药业股份有限公司向港交所递交招股书，拟主板IPO上市，中金公司为其独家保荐人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2024-12-16/doc-inczsfym5678477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0265","BK0188","BK0012","600673","BK0003","BK0070","BK0028"],"gpt_icon":0},{"id":"2491662374","title":"东阳光12月16日主力资金流入224万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491662374","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491662374?lang=zh_cn&edition=full","pubTime":"2024-12-16 15:18","pubTimestamp":1734333502,"startTime":"0","endTime":"0","summary":"12月16日, 东阳光股价跌1.23%，报收8.82元，成交金额1.64亿元，换手率0.61%，振幅3.58%，量比0.70。东阳光今日主力资金净流入224万元，连续5日净流入，上一交易日主力净流入1073万元，今日环比减少79.12%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为80.00%，平均涨幅为1.97%。该股近5个交易日上涨3.04%，主力资金累计净流入8538万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.12亿元，其中净流入天数为16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152352a1f258e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216152352a1f258e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600673","BK0070","BK0028","BK0188","BK0003","BK0265","BK0012"],"gpt_icon":0},{"id":"2491389536","title":"东阳光药上市在即：深筑差异化创新壁垒，研产销一体化竞争优势催化价值成长","url":"https://stock-news.laohu8.com/highlight/detail?id=2491389536","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491389536?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:50","pubTimestamp":1734321027,"startTime":"0","endTime":"0","summary":"依托长期积累的集研产销及国际合作于一体的体系化竞争优势，东阳光药正不断扩大创新生物药版图，通过持续的业绩增长和创新研发进一步巩固公司体系化竞争优势，构成公司持续增长的飞轮。实际上，上述提到的克立福替尼只是近年来东阳光药差异化创新管线研发的一个缩影。这充分验证了东阳光药创新性研发的可持续性，而其凭借的便是公司建立的极具竞争力的研发平台优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600673","BK0188","BK0070","BK0003","BK0012","BK0265","BK0028"],"gpt_icon":0},{"id":"2491342788","title":"东阳光药冲刺港交所上市：上半年营收、利润双降，张寓帅子承父业","url":"https://stock-news.laohu8.com/highlight/detail?id=2491342788","media":"贝多财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491342788?lang=zh_cn&edition=full","pubTime":"2024-12-13 16:53","pubTimestamp":1734079980,"startTime":"0","endTime":"0","summary":"12月11日，广东东阳光药业股份有限公司递交招股书，准备在港交所上市，中金公司为其保荐人。据贝多财经了解，东阳光药拟以介绍形式在港交所主板挂牌上市。同时，东阳光药已向港交所申请以介绍方式将H股上市。完成换股后，东阳光长江药业的上市地位将被撤销。具体而言，该公司2024年上半年的营收同比减少20.7%，净利润亦同比下降15.5%。其中，张寓帅为东阳光药非执行董事，郭梅兰为张寓帅的母亲，二者为东阳光药的实际控制人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2024-12-13/doc-inczieft9149310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600673"],"gpt_icon":0},{"id":"2491399077","title":"东阳光药整合上市全面加速，实现1+1＞2？","url":"https://stock-news.laohu8.com/highlight/detail?id=2491399077","media":"乐居财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491399077?lang=zh_cn&edition=full","pubTime":"2024-12-13 09:45","pubTimestamp":1734054300,"startTime":"0","endTime":"0","summary":"历时半年多，东阳光药合并换股事项有了实质性的进展。早前，东阳光药提出私有化方案，以吸收合并方式将港股上市企业东阳光长江药业私有化。根据最新的公告，东阳光药已经达成合并协议的前提条件之一，即股东大会获已于12月11日批准合并事项。当下，东阳光药致力于完成有关备案及注册，并取得相关批准。与此同时，东阳光药已向港交所提出申请上市，并发布了最新的招股书。而东阳光药如若实现整体上市，或能令股价有新的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/zc/2024-12-13/doc-inczhtrx9246570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0188","BK0070","BK0012","BK0003","BK0265","600673"],"gpt_icon":0},{"id":"2490338388","title":"东阳光药业冲刺港股：上半年营收25.8亿 同比降20.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338388","media":"腾讯自选股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490338388?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:41","pubTimestamp":1734014460,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 12月12日广东东阳光药业股份有限公司日前递交招股书，准备在港交所上市。招股书显示，东阳光药业2021年、2022年、2023年营收分别为10.58亿元、38.14亿、63.86亿；毛利分别为5.81亿元、29.22亿元、50.77亿元。东阳光药业2024年上半年营收为25.82亿元，较上年同期的32.57亿元下降20.7%；经营利润为7.38亿元，较上年同期的11亿元下降32.9%；期内利润为4.73亿元，较上年同期的5.6亿元下降15.5%。截至2024年6月30日，东阳光药业持有的现金及现金等价物为16亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-12-12/doc-inczfsee9427502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600673","YANG","07226","HSCEI","HSTECH"],"gpt_icon":1},{"id":"2490338884","title":"医健IPO解码｜手握流感“神药”，东阳光药递交港交所上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338884","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490338884?lang=zh_cn&edition=full","pubTime":"2024-12-12 20:18","pubTimestamp":1734005880,"startTime":"0","endTime":"0","summary":"在研发队伍上，东阳光药有超过1100名研发人员，截至今年6月30日，其申请2403项发明专利，已获得授权的境内外发明专利共计1351项。根据弗若斯特沙利文报告，以2014年1月1日至2023年12月31日在中国公布的专利数量及授权专利公告数量统计，东阳光药在中国制药公司中排名第一。头豹研究院发布的报告指出，截至2023年年中奥司他韦成分药品占流感用药97.5%的销售份额。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-12-12/doc-inczffqk9648126.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-12-12/doc-inczffqk9648126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0003","BK0028","BK0070","600673","BK0188","BK0012","BK0265"],"gpt_icon":0},{"id":"2490737888","title":"港股异动 | 东阳光长江药业(01558)盘中涨近9% 控股股东东阳光药业递交招股书 拟以介绍方式在港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2490737888","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490737888?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:36","pubTimestamp":1733989017,"startTime":"0","endTime":"0","summary":"消息面上，12月11日，东阳光长江药业控股股东东阳光药向港交所递交招股书，拟以介绍方式在港上市。值得注意的是，今年5月10日，东阳光长江药业曾与东阳光药发布联合公告，宣布二者已于当日订立合并协议。完成换股后，东阳光长江药业H股在港交所的上市地位将被撤销，换股股东将成为东阳光药股东，并且东阳光长江药业最终将在中国注销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01558","600673","BK0028","BK0070","BK1515","BK1191","BK0188","BK0003","BK0265","BK0012"],"gpt_icon":0},{"id":"2490338933","title":"东阳光12月12日主力资金流入1452万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2490338933","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490338933?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:17","pubTimestamp":1733987859,"startTime":"0","endTime":"0","summary":"东阳光今日主力资金净流入1452万元，连续3日净流入，上一交易日主力净流入3646万元，今日环比减少60.18%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为58.33%，平均涨幅为1.74%。该股近5个交易日上涨0.22%，主力资金累计净流入6597万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2.20亿元，其中净流入天数为16日。该行业中净流入前三个股分别为综艺股份、东阳光、红棉股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212152008ab71b9c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212152008ab71b9c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0003","BK0070","BK0012","BK0188","600673","BK0265","BK0028"],"gpt_icon":0},{"id":"2490827594","title":"东阳光药向香港交易所提交招股书 以介绍方式上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2490827594","media":"观点地产网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490827594?lang=zh_cn&edition=full","pubTime":"2024-12-12 14:11","pubTimestamp":1733983860,"startTime":"0","endTime":"0","summary":"观点网讯：12月12日，东阳光长江药业控股股东东阳光药向香港交易所提交上市申请，计划通过介绍方式在港交所挂牌上市，独家保荐人为中金公司。东阳光药成立于2003年，是一家综合性制药公司，专注于创新药，亦涉及改良型新药、仿制药和生物类似药，战略性专注于感染、慢病及肿瘤等治疗领域。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2024-12-12/doc-inczeuyq9750524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0516422366.SGD","HKXCY","LU0370786039.SGD","LU0791590937.USD","600673","IE00B3T34201.USD","IE00BZ08YT58.USD","LU1226287529.USD","LU0577902611.USD","SG9999001093.SGD","LU2257852520.SGD","LU0516423091.SGD","LU0831093199.SGD","IE00BZ08YR35.GBP","BK0028","LU0327786744.USD","LU0561508036.HKD","LU0197773673.USD","LU0348735423.USD","LU0348827113.USD","BK0012","LU0348825331.USD","LU0417516738.SGD","LU0211977185.USD","LU0634319403.HKD","LU0630378692.HKD","LU0140636845.USD","LU0650527681.SGD","LU2039709279.SGD","BK1131","80388","LU0762540952.USD","LU0072913022.USD","LU1366334578.USD","LU0577902538.SGD","LU0067412154.USD","LU0918141705.HKD","LU2226246903.HKD","LU0630378429.USD","LU0516422952.EUR","BK1589","LU0417516902.SGD","LU0540923850.HKD","LU0577902298.EUR","SG9999001846.SGD","LU1282648689.USD","00388","LU0501845795.SGD","BK0003","LU0516422440.USD"],"gpt_icon":0},{"id":"2490821726","title":"东阳光药递交招股书 拟以介绍方式在港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2490821726","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490821726?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:44","pubTimestamp":1733982272,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0028","BK0276","BK0070","BK0188","BK0003","03908","BK1147","BK1501","BK1564","BK1516","SG9999002828.SGD","600673","BK1191","601995","BK1515","01558","BK0012","BK0265"],"gpt_icon":0},{"id":"2490822565","title":"东阳光药业拟重组东阳光长江药业并以介绍形式香港上市，递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2490822565","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490822565?lang=zh_cn&edition=full","pubTime":"2024-12-12 13:39","pubTimestamp":1733981940,"startTime":"0","endTime":"0","summary":"2024年12月11日，广东东阳光药业股份有限公司SUNSHINE LAKE PHARMA CO., LTD.在港交所递交上市申请，拟以介绍形式在香港主板挂牌上市。东阳光药业目前拥有东阳光长江药业的51.41%股权。东阳光药业已提出私有化方案，以吸收合并的方式将东阳光长江药业私有化，将根据换股比率向全体换股股东发行H股，作为换股的对价。完成换股后，东阳光长江药业的上市地位将被撤销。招股书显示，东阳光药业在私有化东阳光药业完成前及上市前的股东架构，","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2024-12-12/doc-inczeuyq9750645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600673","BK0188","BK1515","BK0070","BK0003","BK0012","BK0265","BK1191","01558","BK0028"],"gpt_icon":0},{"id":"2490386787","title":"【新股IPO】广东东阳光药业向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2490386787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490386787?lang=zh_cn&edition=full","pubTime":"2024-12-12 00:27","pubTimestamp":1733934474,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所12月11日披露，广东东阳光药业向港交所主板提交上市申请，中金公司为独家保荐人。公司是一家综合性制药公司，从事药物的研发、生产和商业化，专注于创新药，亦涉及改良型新药、仿制药和生物类似药。公司也是凭藉自主研发成功实现一款1类创新药上市，三款1类创新药申请上市的少数中国制药公司之一。","market":"sh","thumbnail":"https://static.szfiu.com/news/20220324/ZjM0ZDc5YjRlZDkyZDRiYzkwYjYwYTUxMjg3NTcxMDQwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/ZjM0ZDc5YjRlZDkyZDRiYzkwYjYwYTUxMjg3NTcxMDQwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949456","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0003","BK0188","600673","BK0265","BK0070","BK0028","BK0012"],"gpt_icon":0},{"id":"2490855351","title":"即将登陆港股市场，挖掘东阳光药研产销一体化创新布局背后的投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2490855351","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490855351?lang=zh_cn&edition=full","pubTime":"2024-12-11 20:05","pubTimestamp":1733918719,"startTime":"0","endTime":"0","summary":"目前，东阳光药在全球已获批药物147款，在研药物超过100款，其中包含45款1类创新药，1款新药已经上市，3款新药申请上市，10款新药处于临床II、III期阶段。对于投资者而言，东阳光药顺利登陆港股市场后，有望凭借其强劲的研产销一体化竞争优势、充满想象空间的创新研发布局以及丰厚的现金流支撑，推动公司估值增长迈向新台阶，为港股投资者带来不同的投资选择以及更好的投资回报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0003","BK0012","YANG","BK0028","07226","HSTECH","BK0070","HSCEI","BK0265","600673"],"gpt_icon":1},{"id":"2489612286","title":"东阳光12月06日主力资金流入2698万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2489612286","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489612286?lang=zh_cn&edition=full","pubTime":"2024-12-06 15:18","pubTimestamp":1733469489,"startTime":"0","endTime":"0","summary":"12月06日, 东阳光股价跌0.22%，报收8.90元，成交金额2.00亿元，换手率0.75%，振幅2.69%，量比0.63。东阳光今日主力资金净流入2698万元，连续3日净流入，上一交易日主力净流入1287万元，今日环比增加109.63%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为63.64%，平均涨幅为1.74%。该股近5个交易日上涨7.23%，主力资金累计净流入1.32亿元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入2.37亿元，其中净流入天数为17日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206152135a1d880b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206152135a1d880b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0012","BK0265","BK0028","BK0003","BK0188","600673"],"gpt_icon":0},{"id":"2489494678","title":"东阳光（600673）2名股东合计质押7300万股，占总股本2.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489494678","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489494678?lang=zh_cn&edition=full","pubTime":"2024-12-06 03:26","pubTimestamp":1733426791,"startTime":"0","endTime":"0","summary":"证券之星消息，东阳光12月6日公开信息显示，股东深圳市东阳光实业发展有限公司、宜昌东阳光药业股份有限公司向广东顺德农村商业银行股份有限公司容桂支行合计质押7300.0万股，占总股本2.42%。东阳光主营业务：电子元器件、高端铝箔、化工新材料、能源材料四大板块。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120600003911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0003","600673","BK0070","BK0265","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1993-09-17","address":"广东省韶关市乳源瑶族自治县乳城镇侯公渡","stockEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.1024},{"period":"3month","weight":0.4432},{"period":"6month","weight":0.2466},{"period":"1year","weight":0.4208},{"period":"ytd","weight":0.3025}],"companyName":"广东东阳光科技控股股份有限公司","boardCode":"AI0090","perCapita":"61983股","boardName":"综合","registeredCapital":"301387万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 广东东阳光科技控股股份有限公司的主营业务为电子元器件、高端铝箔、化工新材料、能源材料四大板块业务。主要产品有铝电解电容器用电极箔(包含腐蚀箔和化成箔)、积层箔、铝电解电容器、软磁材料、电子光箔、亲水箔、钎焊箔、电池铝箔、氯碱化工产品、新型环保制冷剂、磷酸铁锂、三元材料等。公司被评为国家技术中心(“广东省工程技术研发中心”)。","serverTime":1734689216173,"listedPrice":3.8,"stockholders":"48425人(较上一季度增加1.30%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东阳光(600673)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东阳光(600673)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东阳光,600673,东阳光股票,东阳光股票老虎,东阳光股票老虎国际,东阳光行情,东阳光股票行情,东阳光股价,东阳光股市,东阳光股票价格,东阳光股票交易,东阳光股票购买,东阳光股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东阳光(600673)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东阳光(600673)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}